Intragastric Balloon: Ethics, Medical Need and Cosmetics

Kotzampassi, Katerina; Shrewsbury, Anne D.

doi:10.1159/000109386

Cited by 12 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGB models approved for use in most countries include “traditional” fluid filled (6 mo and one year), adjustable fluid filled (one year), and air filled (6 mo). The mechanism of action of IGBs is not yet fully established; however, it is believed that it is related to three factors: (1) Mechanical restriction, decreasing gastric capacity and leading to an increase in gastric emptying time, resulting in early satiety; (2) Hormonal changes due to direct contact with the gastric fundus, leading to a decrease in ghrelin and an increase in cholecystokinin, altering appetite and gastric emptying; and (3) Neurogenic, via central stimulation of the paraventricular nucleus of the solitary tract through vagal stimulation[ 8 ].…”

Section: Resultsmentioning

confidence: 99%

Status of bariatric endoscopy–what does the surgeon need to know? A review

Dantas¹,

Ribeiro²,

McCarty³

et al. 2022

WJGS

View full text Add to dashboard Cite

BACKGROUND Obesity is a chronic and multifactorial disease with a variety of potential treatment options available. Currently, there are several multidisciplinary therapeutic options for its management, including conservative, endoscopic, and surgical treatment. AIM To clarify indications, technical aspects, and outcomes of bariatric endoscopy. METHODS Narrative review of current literature based on electronic databases including MEDLINE (PubMed), Cochrane Library, and SciELO. RESULTS Bariatric endoscopy is in constant development and comprises primary and revisional treatment options as well as management of surgical complications. Various devices act upon different mechanisms of action, which may be individualized to each patient. Despite favorable results for the endoscopic treatment of obesity, prospective randomized studies with long-term follow-up are required to fully validate primary and revisional endoscopic therapies. Regarding the management of bariatric surgery complications, endoscopic therapy may be considered the procedure of choice in a variety of situations. Still, as there is no standardized algorithm, local experience should be considered in decision-making. CONCLUSION The treatment of patients with obesity is complex, and a multidisciplinary approach is essential. Bariatric endoscopy has shown impressive results both in the treatment of obesity and its surgical complications, and therefore, must be part of the armamentarium in the fight against this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Status of bariatric endoscopy–what does the surgeon need to know? A review

Dantas¹,

Ribeiro²,

McCarty³

et al. 2022

WJGS

View full text Add to dashboard Cite

show abstract

“…Thus, IGB insertion represents a generally safe, easy to perform, adjustable, reversible, and reproducible endoscopic gastric restriction procedure, successfully applied for weight loss over the last 30 years. It covers a broad spectrum of indications from the overweight to the obese individual who does not fulfill the criteria for bariatric surgery, up to the morbidly obese, who qualifies for bariatric surgery but has uncontrolled co-morbidities causing her/him to be of high-risk for anesthesia and surgery or denied anesthesia and/or surgery, or its use as a bridge to bariatric surgery, and, finally, to anyone who just needs to achieve limited weight reduction, either prior to surgery of whatever kind and for whatever reason or merely for aesthetic purposes[ 51 , 82 , 83 ]. Generally speaking, the specific indications for balloon implantation for each candidate for such treatment must be built on the absolute judgment of the treating physician or the multidisciplinary working team; however, the positive response, that is the weight loss, is due exclusively to the responsibility of the patient to strictly adhere to a diet/exercise program and follow-up sessions throughout the treatment period, whatever type of balloon has been used.…”

Section: Discussionmentioning

confidence: 99%

Six intragastric balloons: Which to choose?

Stavrou¹,

Shrewsbury²,

Kotzampassi³

2021

WJGE

Self Cite

View full text Add to dashboard Cite

Endoscopically placed intragastric balloons (IGBs) have played a significant role in obesity treatment over the last 30 years, successfully bridging the gap between lifestyle modification/pharmacotherapy and bariatric surgery. Since they provide a continuous sensation of satiety that helps the ingestion of smaller portions of food, facilitating maintenance of a low-calorie diet, they have generally been considered an effective and reversible, less invasive, non-surgical procedure for weight loss. However, some studies indicate that balloons have limited sustainable effectiveness for the vast majority attempting such therapy, resulting in a return to the previous weight after balloon removal. In this review we try to summarize the pros and cons of various balloon types, to guide decision making for both the physician and the obese individual looking for effective treatment. We analyzed the six most commonly used IGBs, namely the liquid-filled balloons Orbera, Spatz3, ReShape Duo and Elipse, and the gas-filled Heliosphere and Obalon - also including comments on the adjustable Spatz3, and the swallowable Obalon and Elipse - to optimize the choice for maximum efficacy and safety.

show abstract

“…The IGB has been also used as preparation for major surgical procedures to minimize anesthesia risk [6], and it has been indicated that it can be safely applied in morbidly obese patients before bariatric procedures to decrease morbidity and mortality following definitive surgery [12,13]. Left hepatic lobe volume decrease facilitates the laparoscopic procedures [3].…”

Section: Discussionmentioning

confidence: 99%

“…The method had to be abandoned in the late 1980s in the USA because of complications, but research continued in Europe resulting in a better understanding of its effects and the definition of suitable patients [2]. The potential benefit of IGB treatment is a sustained 5-10% weight loss in order to prevent obesity, and related co-morbidities and diseases [3]. Many years of research and design modifications have resulted in a growing interest from surgeons in recent years and increased use of IGB treatment [2].…”

Section: Introductionmentioning

confidence: 99%

“…Many years of research and design modifications have resulted in a growing interest from surgeons in recent years and increased use of IGB treatment [2]. However, many complications have been reported in relation to this procedure, and it is important to be familiar with managing these problems since they cannot be entirely avoided despite the best efforts [3][4][5][6][7]. In this report, we outline the results of 31 cases of IGB treatment for obesity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intragastric Balloon Treatment for Obesity: Prospective Single-Center Study Findings

Peker

Durak

Özgürbüz³

2010

Obes Facts

View full text Add to dashboard Cite

Background: The intragastric balloon (IGB) procedure is an obesity treatment. Methods: A BioEnteric IGB was used in 33 patients between February 2006 and February 2009. Results: Of the 31 patients, 19 were female (61.3%). Mean age was 35.48 ± 9.31 years. Following intravenous sedation, the balloon was inserted and inflated under direct vision by using saline (600 ml) and methylene blue (10 ml) solution. Average weight and mean BMI scores were as follows: 119.34 ± 22.64 (range 80–170) kg and 41.84 ± 8.28 (range 30–63.2) kg/m². Mean weight and BMI were measured as 104.31 ± 21.33 (range 64–151) kg and 36.43 ± 7.36 (range 26–52) kg/m² 6 months after the index procedure. Percent of excess weight loss (%EWL) and percent of excess body mass index loss (%EBMIL) were as follows: 29.16 ± 15.99% (range 0.00–56.91%) and 35.45 ± 19.46% (0–75.2%), respectively. All patients lost weight constantly for the 6-month period. Patients showed statistically significant weight and BMI losses for the first 3-month period but these decrements reached a plateau between the 4th and 6th month. Weight loss was not statistically significant during the second 3-month period. Few patients had mild complaints following balloon insertion; there was no balloon intolerance. Conclusions: IGB is safe and effective for short-term weight reduction in obese patients. Weight reduction during the second half of the treatment period needs closer follow-up.

show abstract

Intragastric Balloon: Ethics, Medical Need and Cosmetics

Cited by 12 publications

References 18 publications

Status of bariatric endoscopy–what does the surgeon need to know? A review

Status of bariatric endoscopy–what does the surgeon need to know? A review

Six intragastric balloons: Which to choose?

Intragastric Balloon Treatment for Obesity: Prospective Single-Center Study Findings

Contact Info

Product

Resources

About